Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
European Respiratory Review 2018 March [Print 2018 March 31] Link] Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C Abstract Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have…Read More
The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database
International Journal of Surgery 2017 October [Epub ahead of print] [Link] Wang S, Ma K, Wang Q, Sun F, Shi Y, Zhan C, Jiang W Abstract BACKGROUND: Several staging systems for MPM have been introduced. However, none of them provide perfect survival stratification among heterogeneous patients. The aim of this population-based cohort study was to…Read More
Advances in systemic therapy for malignant mesothelioma: future perspectives
Future Oncology 2017 October [Epub ahead of print] [Link] Sobhani N, Corona SP, Bonazza D, Ianza A, Pivetta T, Roviello G, Cortale M, Guglielmi A, Zanconati F, Generali D Abstract Malignant mesothelioma is a rare and aggressive form of cancer affecting the mesothelium. This mainly occupational disease is becoming more common in those countries where…Read More
The value of delayed phase enhanced imaging in malignant pleural mesothelioma
Journal of Thoracic Disease 2017 August [Link] Patel AM, et.al. Abstract BACKGROUND: Cross-sectional imaging of malignant pleural mesothelioma (MPM) can underestimate the presence of local tumor invasion. Since accurate staging is vital optimal choice of therapy, techniques that optimize pleural imaging are needed. Here we estimate the optimal timing of MPM enhancement on magnetic resonance…Read More
Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining
Cancer. 2017 September 18 [Epub ahead of print] [Link] Mansour MSI, Seidal T, Mager U, Baigi A, Dobra K, Dejmek A Abstract BACKGROUND: Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD-L1) is a dominant mediator of immunosuppression, binding to programmed cell death…Read More
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Archives of pathology and laboratory medicine 2017 July [Epub ahead of print] [Link] Husain AN et.al. Abstract CONTEXT: – Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: – To provide updated, practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: – Pathologists involved in the International Mesothelioma Interest…Read More
Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma
Oncotarget 2017 June [Epub ahead of print] [Link] Jacobson BA, Sadiq AA, Tang S, Jay-Dixon J, Patel MR, Drees J, Sorenson BS, Russell SJ, Kratzke RA Abstract Malignant mesothelioma has a poor prognosis for which there remains an urgent need for successful treatment approaches. Infection with the Edmonston vaccine strain (MV-Edm) derivative of measles virus…Read More
Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer.
Tumor Biology 2017 June [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28618948″>Link Wang XY, Wang Z, Huang JB, Ren XD, Ye D1,, Zhu WW, Qin LXM Abstract BAP1 is an emerging tumor suppressor whose inactivating mutations have been found to play critical roles in tumor development. This study was conducted to elucidate the potential value of BAP1 mutation in guiding prognostic…Read More
A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.
Cancer Genomics & Protemics 2017 March [Link] Creaney J, Dick IM, Leon JS, Robinson BW Abstract Abstract Backgound/Aim: Malignant mesothelioma (MM) is an aggressive and fatal pleural cancer. The cell secretome offers information allowing insight into the pathogenesis of MM while offering the possibility to identify potential therapeutic targets and biomarkers. In the present study…Read More
Recommendations for the Diagnosis and Management of Asbestos-Related Pleural and Pulmonary Disease
Archivos de Bronconeumologia 2017 March 6 [Epub ahead of print] [Link] Diego Roza C, Cruz Carmona MJ, Fernández Álvarez R, Ferrer Sancho J, Marín Martínez B, Martínez González C, Rodríguez Portal JA, Romero Valero F, Villena Garrido V Abstract Asbestos is the term used for a set of mineral silicates that tend to break up…Read More